Formycon partners with OneSource Specialty Pharma for biosimilar manufacturing

• Formycon entered a strategic biosimilars manufacturing partnership with OneSource Specialty Pharma on July 14, 2026.
• OneSource will provide integrated drug substance, drug product manufacturing from its biologics facility in Bangalore to support Formycon’s global biosimilar programs.
• Partnership targets scalable, cost-efficient supply to strengthen manufacturing capacity under Formycon’s FYB4Growth strategy.
• OneSource brings end-to-end biologics capabilities from cell line development to commercial fill-finish across facilities cleared by US FDA, EMA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Formycon AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2364852_en) on July 14, 2026, and is solely responsible for the information contained therein.